Off-the-Shelf CAR T-Cell Therapy Shows Promise in Relapsed/Refractory B-Cell Lymphomas

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial.

Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Conor Killmurray Source Type: news